

comments on or objections to the issuance of the proposed registration on or before April 9, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on July 21, 2017, Chattem Chemicals, Inc., 3801 St. Elmo Avenue, Chattanooga, Tennessee 37409 applied to be registered as a bulk manufacturer for the basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid.	2010	I
Marihuana	7360	I
Tetrahydrocannabinols ...	7370	I
4-Methoxyamphetamine	7411	I
Dihydromorphine	9145	I
Amphetamine	1100	II
Methamphetamine	1105	II
Lisdexamfetamine	1205	II
Methylphenidate	1724	II
Pentobarbital	2270	II
Codeine	9050	II
Dihydrocodeine	9120	II
Oxycodone	9143	II
Hydromorphone	9150	II
Hydrocodone	9193	II
Meperidine	9230	II
Meperidine intermediate-A.	9232	II
Meperidine intermediate-B.	9233	II
Meperidine intermediate-C.	9234	II
Methadone	9250	II
Methadone intermediate	9254	II
Morphine	9300	II
Oripavine	9330	II
Thebaine	9333	II
Opium tincture	9630	II
Opium, powdered	9639	II
Opium, granulated	9640	II
Oxymorphone	9652	II

Controlled substance	Drug code	Schedule
Noroxymorphone	9668	II
Alfentanil	9737	II
Remifentanil	9739	II
Sufentanil	9740	II
Tapentadol	9780	II
Fentanyl	9801	II

The company plans to manufacture the listed controlled substances in bulk for distribution and sale to its customers.

In reference to drug codes 7360 (marihuana) and 7370 (tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration.

Dated: January 30, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.

[FR Doc. 2018–02343 Filed 2–5–18; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–392]

Bulk Manufacturer of Controlled Substances Application: Cedarburg Pharmaceuticals

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before April 9, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion

Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on August 29, 2017, Cedarburg Pharmaceuticals, Inc., A Division of Albany Molecular Research Inc. (AMRI), 870 Badger Circle, Grafton, Wisconsin 53024 applied to be registered as a bulk manufacturer the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Marihuana	7360	I
Tetrahydrocannabinols ...	7370	I
Lisdexamfetamine	1205	II
Pentobarbital	2270	II
Nabilone	7379	II
4-Anilino-N-phenethyl-4-piperidine (ANPP).	8333	II
Remifentanil	9739	II
Fentanyl	9801	II

The company plans to manufacture the above listed controlled substances in bulk for distribution to its customers. In reference to drug codes 7360 marihuana, the company plans to bulk manufacture cannabidiol as a synthetic intermediate. The company plans to manufacture bulk active pharmaceutical ingredients (API) for distribution to its customers. This controlled substance will be further synthesized to bulk manufacture a synthetic tetrahydrocannabinols 7370. No other activity for this drug code is authorized for this registration.

Dated: January 30, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.

[FR Doc. 2018–02341 Filed 2–5–18; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Notice of Proposed Settlement Agreement and Draft Restoration Plan Under The Oil Pollution Act of 1990, and The Clean Water Act

Notice is hereby given that the United States of America, on behalf of the Department of the Interior (“DOI”) acting through the Fish and Wildlife Service and the National Park Service, the District of Columbia, on behalf of the Department of Energy and Environment, and the Commonwealth of Virginia, acting through the Virginia Department of Environmental Quality (collectively “Trustees”), are providing an opportunity for public comment on a proposed Settlement Agreement (“Settlement Agreement”) among the DOI, the District of Columbia, the Commonwealth of Virginia, and

Virginia Electric and Power Company d/ b/a Dominion Energy Virginia (“Dominion Energy”). The Trustees are also providing notice of an opportunity for public comment on a draft Damage Assessment and Restoration Plan (“draft DARP”).

The settlement resolves the civil claims of DOI, the District of Columbia, and the Commonwealth of Virginia against Dominion Energy arising under their natural resource trustee authority under the Oil Pollution Act of 1990 (OPA), 33 U.S.C. 2701 *et seq.*, the natural resource damages provisions of the Clean Water Act, 33 U.S.C. 1321(f)(4) and (5), and applicable state law for injury to, impairment of, destruction of, and loss of use of natural resources as a result of a January 24, 2016 oil spill at the Dominion Energy Crystal City Substation located in Arlington, Virginia (“Oil Spill”). The Oil Spill occurred when a transformer tank ruptured at the Crystal City Substation, spilling approximately 13,500 gallons of mineral oil dielectric fluid, most of which was recovered from the Substation’s containment facility and through response action. The NPS is also acting under its authority under the System Unit Resource Protection Act System, 54 U.S.C. 100723. Further, in accordance with the OPA the Trustees have written a draft DARP that describes proposed alternatives for restoring the natural resources and natural resource services injured by the Oil Spill.

Under the proposed Settlement Agreement, Dominion Energy agrees to pay \$390,385 to the DOI Natural Resource Damage Assessment and Restoration Fund, (established by 43 U.S.C. 1474b), to be used to restore, replace, rehabilitate or acquire the equivalent of, those resources injured by the Oil Spill and to compensate the public for lost recreational opportunities, as proposed in the draft DARP. Dominion Energy will receive from the Trustees a covenant not to sue for the claims resolved by the settlement, including assessment costs.

The publication of this notice opens a period for public comment on the proposed Settlement Agreement and draft DARP. The Trustees will receive comments relating to the Settlement Agreement and draft DARP for a period of thirty (30) days from the date of this publication. A copy of the proposed Settlement Agreement and the draft DARP are available electronically at <https://parkplanning.nps.gov/projectHome.cfm?projectID=75342>. A copy of the proposed Settlement Agreement and draft DARP may be examined at the George Washington

Memorial Parkway office. Arrangements to view the documents must be made in advance by contacting the Natural Resource Division at (703) 289-2500. A copy of the Settlement Agreement only may also be obtained by mail from:

Assistant Solicitor, Environmental Restoration Branch, Office of the Solicitor, U.S. Department of the Interior, 1849 C Street NW, Washington, DC 20240.

Please reference: Dominion Energy Virginia Crystal City Substation Settlement Agreement, DOI-SOL-ERB-2018-001. When requesting a copy of the Settlement Agreement please enclose a check in the amount of \$3.25 (25 cents per page reproduction cost) payable to the United States Treasury.

Comments on the proposed Settlement Agreement and/or the draft DARP may be submitted electronically at <https://parkplanning.nps.gov/projectHome.cfm?projectID=75342>. Additionally, written comments on the proposed Settlement Agreement and/or draft DARP should be addressed to Superintendent, George Washington Memorial Parkway Headquarters, Attn. Dominion DARP, 700 George Washington Memorial Parkway, McLean, VA 22101.

Robert Brook,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 2018-02263 Filed 2-5-18; 8:45 am]

BILLING CODE 4410-15-P

DEPARTMENT OF JUSTICE

Parole Commission

Sunshine Act Meeting

TIME AND DATE: 12:00 a.m., Tuesday, February 13, 2018.

PLACE: U.S. Parole Commission, 90 K Street NE, 3rd Floor, Washington, DC.

STATUS: Closed.

MATTERS TO BE CONSIDERED: Determination on TWO original jurisdiction cases.

CONTACT PERSON FOR MORE INFORMATION: Jacqueline Graham, Staff Assistant to the Chairman, U.S. Parole Commission, 90 K Street NE, 3rd Floor, Washington, DC 20530, (202) 346-7001.

Dated: February 2, 2018.

Patricia K. Cushwa,

Vice Chairman, U.S. Parole Commission.

[FR Doc. 2018-02450 Filed 2-2-18; 4:15 pm]

BILLING CODE 4410-31-P

DEPARTMENT OF JUSTICE

Parole Commission

Sunshine Act Meeting

TIME AND DATE: 11:00 a.m. Tuesday, February 13, 2018.

PLACE: U.S. Parole Commission, 90 K Street NE, 3rd Floor, Washington, DC.

STATUS: Open.

MATTERS TO BE CONSIDERED: Approval of September 26, 2017 minutes; Reports from the Vice Chairman, Commissioners and Senior Staff; Discussion of potential amendment to 28 CFR 2.25 to permit hearings by videoconference to include parole and supervised release termination hearings; Discussion of potential modification of 28 CFR 2.68(i)(1) to require one Commissioner vote for Transfer Treaty determinations.

CONTACT PERSON FOR MORE INFORMATION: Jacqueline Graham, Staff Assistant to the Chairman, U.S. Parole Commission, 90 K Street NE, 3rd Floor, Washington, DC 20530, (202) 346-7010.

Dated: February 2, 2018.

Patricia K. Cushwa,

Vice Chairman, U.S. Parole Commission.

[FR Doc. 2018-02448 Filed 2-2-18; 4:15 pm]

BILLING CODE 4410-31-P

NATIONAL SCIENCE FOUNDATION

Sunshine Act Meeting; National Science Board

The National Science Board’s Committee on External Engagement (EE), pursuant to NSF regulations (45 CFR part 614), the National Science Foundation Act, as amended (42 U.S.C. 1862n-5), and the Government in the Sunshine Act (5 U.S.C. 552b), hereby gives notice of the scheduling of a teleconference for the transaction of National Science Board business, as follows:

TIME AND DATE: Thursday, February 8, 2018 at 10:00-11:00 a.m. EST.

PLACE: This meeting will be held by teleconference at the National Science Foundation, 2415 Eisenhower Avenue, Alexandria, VA 22314. An audio link will be available for the public. Members of the public must contact the Board Office to request the public audio link by sending an email to nationalsciencebrd@nsf.gov at least 24 hours prior to the teleconference.

STATUS: Open.

MATTERS TO BE CONSIDERED: Discuss possible future National Science Board listening sessions as well as other priorities in preparation for the February board meeting.